Evotec, Takeda Enter Multi-Target Pact

Evotec AG has entered into a collaboration with Takeda Cambridge Ltd., to identify small molecule modulators against GPCR and Protease targets to treat various CNS and Metabolic diseases. Financial terms were not disclosed. Evotec will apply its screening platform and GPCR modeling software to identify and validate novel modulators against various targets selected by Takeda.

Dr. Mario Polywka, chief operating officer at Evotec said, “We are proud to be selected by Takeda Cambridge to collaborate on this important project. We have invested significantly in our world leading, hit-identification platform and this alliance further validates the strength of this platform and Evotec’s ability to bring value to its partners’ drug discovery efforts. We look forward to working with Takeda Cambridge.”

Dr. Andrew Ayscough, director of chemistry at Takeda Cambridge, said, “We are pleased to have this opportunity to work with Evotec making use of their hit identification platform.”